Meeting
2019 ASCO Annual Meeting
A phase I study of neoadjuvant combination immunotherapy in locally/regionally advanced melanoma.
Authors
Yana Najjar
University of Pittsburgh, Pittsburgh, PA
Yana Najjar , Dustin McCurry , Huang Lin , Yan Lin , Diwakar Davar , Joseph J. Drabick , Rogerio Izar Neves , Marc S. Ernstoff , Igor Puzanov , Joseph J. Skitzki , James F. Pingpank Jr., Matthew Peter Holtzman , Cindy Sander , Amy Rose , John M. Kirkwood , Ahmad A. Tarhini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT02339324
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9586)
DOI
10.1200/JCO.2019.37.15_suppl.9586
Abstract #
9586
Poster Bd #
157
Abstract Disclosures
Similar Posters
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Neoadjuvant combination immunotherapy with pembrolizumab and high dose IFN-α2b in locally/regionally advanced melanoma.
First Author: Ahmad A. Tarhini
First Author: Igor Tsaur
Poster
2023 ASCO Annual Meeting
A phase 2 study of alrizomadlin (APG-115) in combination with pembrolizumab in patients with unresectable or metastatic cutaneous melanoma that has failed immuno-oncologic (IO) drugs.
First Author: Montaser F. Shaheen
Poster
2016 ASCO Annual Meeting
Neoadjuvant combination immunotherapy with ipilimumab (3 mg/kg or 10mg/kg) and high dose IFN-a2b in locally/regionally advanced melanoma.
First Author: Ahmad A. Tarhini